Vaxxas Inc.

7 articles with Vaxxas Inc.

• Vaxxas Announces $22 Million Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

  10/5/2020

  Needle-free Vaxxas HD-MAP patch offers potential platform to dramatically improve vaccination in pandemic response by producing more patient-doses from limited quantities of vaccine, enabling rapid vaccine distribution without refrigeration, and creating a novel option for self-administration. Initial BARDA funding focuses on clinical demonstration using pandemic influenza vaccine; Vaxxas investigating opportunities to improve performance of other

• Vaxxas Announces That Merck Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate

  5/28/2020

  Vaxxas Announces That Merck Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate

• Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial-scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD-MAP)

  5/28/2020

  Needle-free Vaxxas HD-MAP can enhance routine vaccination with potential to revolutionize vaccination in pandemic response; produce more patient-doses from limited quantities of vaccine, distribution without refrigeration, and potential for self-administration.

• Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study of Measles and Rubella Vaccination using Vaxxas’ High Density Micro-Array Patch

  3/17/2020

  Funding Accelerates Vaxxas’ Clinical Pipeline of Innovative Vaccines

• Invetech And Vaxxas Inc. Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery

  5/29/2015

• Vaxxas Inc. Grabs $20 Million to Launch Clinical Trials of Vaccine Patch

  2/9/2015

• Vaxxas Inc. Initiates Research Project On Advancing Next Generation Technology For Polio Vaccine Delivery

  9/16/2014